SUNDAY 14TH - TUESDAY 16TH JULY 2019
Please note that there are now only limited places available!
If you wish to register, please contact us directly via the Phase I inbox
The Manchester Cancer Research Centre (MCRC) and the Experimental Cancer Medicine Centres (ECMC) network will be hosting a three-day conference on Phase I, at Hilton Deansgate, in Manchester city centre.
Our keynote speakers include Professor Lillian Siu (Princess Margaret Hospital, Toronto) and Skip Burris (Sarah Cannon Research Institute, Nashville).
The programme can be viewed here.
We are pleased to confirm that this conference has received accreditation by the Federation of the Royal Colleges of Physicians of the United Kingdom and as such attendees will be eligible for up to 18 category 1 (external) CPD credits. Certificates of attendance will be issued by email at the end of the conference.
We would like to thank our sponsors:
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life, safety and survival of patients. Twenty-nine medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. Roche in the UK employs over 2,000 people in pharmaceuticals and diagnostics.
For more information: www.roche.co.uk
Founded in 2016 Carrick Therapeutics is aiming is to create the leading European based biopharmaceutical oncology company. Focusing on innovative research Carrick Therapeutics has a patient focused vision to serve cancer patients around the world by the introduction of ground breaking therapies that will transform the way cancer is treated. Working in partnership with like-minded scientists, collaborators and investors the company has two oncology therapeutics under evaluation in clinical trials - CT7001 and CT900.
CT7001 is a first in class orally bio-available Cyclin-dependent Kinase 7 (CDK7) selective inhibitor, that has shown striking efficacy in multiple pre-clinical cancer models and is in phase 1 clinical development. CT900 is a targeted therapy that combines targeting folate receptor α (FRα) and inhibiting thymidylate synthase. The small molecule compound selectively enters cancer cells that over express folate receptor FRα and patients may be selected via a companion diagnostic based on FRα expression. A lead development program in ovarian cancer is underway.
Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on those living with cancer. As a leader in Oncology speeding cures and accessible breakthrough medicines to patients, Pfizer Oncology is helping to redefine life with cancer. Our strong pipeline of biologics, small molecules and immunotherapies, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners, Pfizer Oncology strives to cure or control cancer with its breakthrough medicines. Pfizer Oncology knows that success in Oncology is not measured solely by the medicines you manufacture, but rather by the meaningful partnerships you make to have a more positive impact on people’s lives.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy.
Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; and multiple locations in Chongqing, China.
For more information, please visit www.athenex.com.
Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley (PA), USA, develops technologies and products that help researchers understand the biological complexity of disease through the study of single cells. The company manufactures and markets the DEPArray NxT, the only image-based digital cell-sorting and isolation platform that enables clinical researchers to conduct molecular analyses on fixed cells with single-cell precision. In 2017 Menarini Silicon Biosystems purchased all the assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell (CTC) System. The integration of CELLSEARCH and DEPArray provides an end-to-end workflow solution* for the enumeration, isolation, and molecular characterization of CTCs from a simple blood test in the clinical research setting. This will help drive the clinical utility and correlation of CTCs with the effectiveness of specific therapies.
*The workflow described is for research use only. Not for use in diagnostic procedures.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com.
Conference Dinner Partner
Sarah Cannon Research Institute is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. Sarah Cannon’s network of strategic sites includes hundreds of physicians who engage in research. With a focus on advancing therapies for patients, the organization has led more than 300 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years.
Additionally, Sarah Cannon offers management, regulatory, and other research support services for drug development and industry sponsors through its contract research organization (CRO), Sarah Cannon Development Innovations. As the CRO of Sarah Cannon, it leverages expert physician leadership to design and implement clinical trials that effectively and efficiently lead to rapid clinical development decisions.
Recharging Station Partner
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.
Aptus Clinical is a UK based, full service, clinical CRO with particular expertise in oncology, rare diseases and advanced (cell and gene) therapies. We specialise in the design, set-up, management and monitoring of early phase clinical trials.
Through our consultancy team we also provide bespoke advice covering development activities from Lead Optimisation through to clinical study/programme design, cost and study placement options. Our Enabling Infrastructure service supports clients with a range of specialist services that include quality management frameworks, clinical governance support and a number of digital solutions that facilitate data storage, analysis and visualisations.
Aptus are partners in iMATCH (innovate Manchester Advanced Therapy Centre Hub), a consortium made up of experts from industry, academia and the NHS and funded by Innovate UK, to help accelerate the safe and effective delivery of advanced therapies to increasing numbers of patients within the NHS. We are also a preferred provider to the Cell and Gene Therapy Catapult.
If you have any enquiries about the conference, please contact Rachel Chown.